CL2015000402A1 - Formulación de comprimidos compuestos de dos fases que comprende irbesartan, atorvastatina y carbonato de magnesio; metodo de preparacion. - Google Patents

Formulación de comprimidos compuestos de dos fases que comprende irbesartan, atorvastatina y carbonato de magnesio; metodo de preparacion.

Info

Publication number
CL2015000402A1
CL2015000402A1 CL2015000402A CL2015000402A CL2015000402A1 CL 2015000402 A1 CL2015000402 A1 CL 2015000402A1 CL 2015000402 A CL2015000402 A CL 2015000402A CL 2015000402 A CL2015000402 A CL 2015000402A CL 2015000402 A1 CL2015000402 A1 CL 2015000402A1
Authority
CL
Chile
Prior art keywords
irbesartan
atorvastatin
phases
formulation
preparation
Prior art date
Application number
CL2015000402A
Other languages
English (en)
Spanish (es)
Inventor
Yong Ii Kim
Jae Hyun Park
Jong Soo Woo
Jun Hyun Cho
Jun Young Choi
Young Keun Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2015000402A1 publication Critical patent/CL2015000402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2015000402A 2012-08-31 2015-02-19 Formulación de comprimidos compuestos de dos fases que comprende irbesartan, atorvastatina y carbonato de magnesio; metodo de preparacion. CL2015000402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제

Publications (1)

Publication Number Publication Date
CL2015000402A1 true CL2015000402A1 (es) 2015-06-05

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000402A CL2015000402A1 (es) 2012-08-31 2015-02-19 Formulación de comprimidos compuestos de dos fases que comprende irbesartan, atorvastatina y carbonato de magnesio; metodo de preparacion.

Country Status (31)

Country Link
US (1) US20150209290A1 (enExample)
EP (1) EP2890368A4 (enExample)
JP (1) JP6363079B2 (enExample)
KR (1) KR20140028971A (enExample)
CN (1) CN104602677A (enExample)
AR (1) AR092386A1 (enExample)
AU (1) AU2013309686B2 (enExample)
BR (1) BR112015004471A8 (enExample)
CA (1) CA2882735A1 (enExample)
CL (1) CL2015000402A1 (enExample)
CR (1) CR20150115A (enExample)
DO (1) DOP2015000040A (enExample)
EA (1) EA030306B1 (enExample)
EC (1) ECSP15010600A (enExample)
GT (1) GT201500043A (enExample)
IL (1) IL237424A0 (enExample)
IN (1) IN2015DN01463A (enExample)
MA (1) MA37951B2 (enExample)
MX (1) MX354800B (enExample)
MY (1) MY175897A (enExample)
NI (1) NI201500027A (enExample)
NZ (1) NZ706472A (enExample)
PE (1) PE20150935A1 (enExample)
PH (1) PH12015500394A1 (enExample)
RU (1) RU2015111546A (enExample)
SG (1) SG11201500584YA (enExample)
TW (1) TWI651101B (enExample)
UA (1) UA115995C2 (enExample)
UY (1) UY35001A (enExample)
WO (1) WO2014035188A1 (enExample)
ZA (1) ZA201502156B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
AU2018301924B2 (en) * 2017-07-17 2021-07-29 Eli Lilly And Company Pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US20030114497A1 (en) 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
KR101230731B1 (ko) * 2008-04-29 2013-02-07 한올바이오파마주식회사 약제학적 제제
WO2011121824A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 口腔内崩壊錠
KR101248804B1 (ko) 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
GT201500043A (es) 2017-08-24
US20150209290A1 (en) 2015-07-30
JP2015530384A (ja) 2015-10-15
MX2015002526A (es) 2015-06-23
ECSP15010600A (es) 2015-12-31
EP2890368A4 (en) 2016-03-02
KR20140028971A (ko) 2014-03-10
PE20150935A1 (es) 2015-06-20
NZ706472A (en) 2018-02-23
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
BR112015004471A8 (pt) 2019-08-27
BR112015004471A2 (pt) 2017-07-04
AU2013309686A1 (en) 2015-02-26
IN2015DN01463A (enExample) 2015-07-03
UY35001A (es) 2014-03-31
MA37951B2 (fr) 2019-12-31
CA2882735A1 (en) 2014-03-06
EP2890368A1 (en) 2015-07-08
DOP2015000040A (es) 2015-04-15
ZA201502156B (en) 2016-07-27
AU2013309686B2 (en) 2017-09-07
JP6363079B2 (ja) 2018-07-25
RU2015111546A (ru) 2016-10-20
WO2014035188A1 (en) 2014-03-06
CN104602677A (zh) 2015-05-06
SG11201500584YA (en) 2015-02-27
AR092386A1 (es) 2015-04-22
NI201500027A (es) 2017-01-04
MY175897A (en) 2020-07-14
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
PH12015500394A1 (en) 2015-04-27
EA030306B1 (ru) 2018-07-31
EA201590469A1 (ru) 2015-06-30
IL237424A0 (en) 2015-04-30
MX354800B (es) 2018-03-22
TWI651101B (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
EP2886652A4 (en) EXTRACTION, PREPARATION AND USE OF A VEGETABLE MICRORIBONUCLEIC ACID
BR112015002738A2 (pt) composto , e , composição farmacêutica
EP2820824A4 (en) DYNAMIC SELECTION OF A SECURITY PROTOCOL
EP2875758A4 (en) JUICER
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
BR112015000527A2 (pt) agente reológico, métodos de preparação e usos dos mesmos.
IL235155B (en) Arginase inhibitor compounds, compositions comprising same and uses thereof
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
EP2915038A4 (en) DELIVERY OF VIRTUALIZED CONTENT
BR112014032488A2 (pt) embalagem, e blanqueta
CL2014003283A1 (es) Formulación farmacéutica.
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112013016135A2 (pt) preparação hemostática contendo um extrato de cibotium barometz.
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
PT2931270T (pt) Extrato de trevo vermelho fermentado e método para produzir o mesmo
BR112014032501A2 (pt) composto, e, composição farmacêutica.
ZA201502157B (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
EP2892367A4 (en) CITRATED CALCIUM MAGNESIUM FOOD SUPPLEMENT AND USES THEREOF
EP2921163A4 (en) OIL-IN-WATER EMULSION COMPOUND
EP2829263A4 (en) OIL EMULSION COMPOSITION IN WATER